André Wieringa

Mr. André Wieringa

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2014 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
PHP. G. J. ter Horst
P. G. J. ter Horst
KBKarin Larmené- Beld
Karin Larmené- Beld
JBJ. Bosman
J. Bosman
EVE. L. van der Veen
E. L. van der Veen
AWAndré Wieringa
André Wieringa
JSJ. P. Smit
J. P. Smit
Depression during pregnancy is common and includes risks for mother and child. Pharmacokinetics of venlafaxine may be changed during pregnancy. This study aimed to describe changes in metabolic ratios and concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during and after pregnancy. To study this, we used data from our study of compliance to Antidepressants During Pregnancy (the ADAP study) to investigate the course of venlafaxine and O-desmethylvenlafaxine concentrations during pregnancy and in the period post-partum. We found that the venlafaxine concentration significantly changed during pregnancy when compared to the post-partum period (P = 0·028). The median concentration of venlafaxine in the first trimester was 98·9% (54·2-292·0%), the second 100·0% (46·5-264·0%) and the third trimester 87·0% (61·5-217·2%). We did not found differences in O-desmethylvenlafaxine concentrations in the different trimesters of pregnancy compared with the post-partum period, P = 0·565. Also the ratio of O-desmethylvenlafaxine/venlafaxine concentrations increased significantly from 76·9% (range 32·8-142·0%) in the first trimester to 196·7% (range 83·3-427·6%) in the third trimester compared with the post-partum period, P = 0·004. Further, three of seven patients had concentrations below the therapeutic reference range (100-400 μg/L) in any period of pregnancy, whereas no one had subtherapeutic concentrations in the post-partum period. Venlafaxine concentrations decreases during pregnancy, and the ratio of the concentrations of O-desmethylvenlafaxine/venlafaxine increases during pregnancy. Pregnant women using venlafaxine are at risk for subtherapeutic concentrations, therefore routine monitoring of concentrations venlafaxine and O-desmethylvenlafaxine is recommendable during pregnancy.

2 December 2025 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
AWAndré Wieringa
André Wieringa
TSTim J.L. Smeets
Tim J.L. Smeets
PHPeter G.J. ter Horst
Peter G.J. ter Horst
NHNicole G.M. Hunfeld
Nicole G.M. Hunfeld
RBRinaldo Bellomo
Rinaldo Bellomo
TTThomas Tangden
Thomas Tangden
Critically ill patients in the intensive care unit represent a highly heterogeneous population with large variations in the pharmacokinetics (PK) of antimicrobials (antibiotics, antifungals, and antiviral agents), complicating optimal dosing strategies. This becomes even more complex in those receiving continuous renal replacement therapy (CRRT), because CRRT significantly alters drug clearance. Nonetheless, many PK studies exclude patients undergoing CRRT and existing studies often suffer from methodological limitations and small sample sizes, reducing their generalizability. Accordingly, there remains a critical gap in robust, evidence-based dosing guidelines for antimicrobials in intensive care unit patients on CRRT, despite the clear clinical need. To conduct a scoping review of the literature on factors affecting the PK of antimicrobials in critically ill patients undergoing CRRT, provide practical recommendations, and develop a CRRT-PK checklist for designing and conducting PK research in this patient group. Embase, Medline, and Cochrane databases, and the reference lists of relevant publications were searched from database inception to 24 June 2025. Data were extracted independently by two reviewers (AW and TJLS) and disagreements were resolved through discussion until consensus was reached. No quality appraisal was performed. Extracted data were synthesized descriptively, grouped by the type of influencing factor (CRRT-, patient-, or drug-related). Of 811 articles identified in the search strategy, a total of 96 articles were included in the review. All relevant CRRT-, patient-, and drug-related factors that may influence the PK of antimicrobials are discussed. Moreover, we provided practical considerations and a CRRT-PK checklist for an appropriate study design and output. This review, along with the checklist, can form the foundation for designing and conducting high-quality PK studies in critically ill patients undergoing CRRT. By improving the consistency and reproducibility of future studies, this is the first step towards robust, evidence-based dosing guidelines for antimicrobials in critically ill patients undergoing CRRT.

28 November 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
AWAndré Wieringa
André Wieringa
TETim M.J. Ewoldt
Tim M.J. Ewoldt
RGRavish Gangapersad
Ravish Gangapersad
MGMatthias Gijsen
Matthias Gijsen
NPNestor Parolya
Nestor Parolya
AAAlan Abdulla
Alan Abdulla
In the intensive care unit (ICU), infection-related mortality is high. Although adequate antibiotic treatment is essential in infections, beta-lactam target non-attainment occurs in up to 45% of ICU patients, which is associated with a lower likelihood of clinical success. To optimize antibiotic treatment, we aimed to develop beta-lactam target non-attainment prediction models in ICU patients. Patients from two multicenter studies were included, with intravenous intermittent beta-lactam antibiotics administered and blood samples drawn within 12–36 h after antibiotic initiation. Beta-lactam target non-attainment models were developed and validated using random forest (RF), logistic regression (LR), and naïve Bayes (NB) models from 376 patients. External validation was performed on 150 ICU patients. We assessed performance by measuring discrimination, calibration, and net benefit at the default threshold probability of 0.20. Age, sex, serum creatinine, and type of beta-lactam antibiotic were found to be predictive of beta-lactam target non-attainment. In the external validation, the RF, LR, and NB models confirmed good discrimination with an area under the curve of 0.79 [95% CI 0.72–0.86], 0.80 [95% CI 0.73–0.87], and 0.75 [95% CI 0.67–0.82], respectively, and net benefit in the RF and LR models. We developed prediction models for beta-lactam target non-attainment within 12–36 h after antibiotic initiation in ICU patients. These online-accessible models use readily available patient variables and help optimize antibiotic treatment. The RF and LR models showed the best performance among the three models tested.

23 March 2015 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
DMDouwe H. van der Meer
Douwe H. van der Meer
AWAndré Wieringa
André Wieringa
IWIlse Wegner
Ilse Wegner
BWBob Wilffert
Bob Wilffert
PHPeter G. J. ter Horst
Peter G. J. ter Horst

10 October 2022 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
AWAndré Wieringa
André Wieringa
PHPeter G J ter Horst
Peter G J ter Horst
GWGertjan H J Wagenvoort
Gertjan H J Wagenvoort
ADAnnemieke Dijkstra
Annemieke Dijkstra
AAAlan Abdulla
Alan Abdulla
BKBirgit C P Koch
Birgit C P Koch
Objectives: Limited data exist about the antimicrobial target attainment and pharmacokinetics of cefotaxime in critically ill patients in the ICU undergoing continuous kidney replacement therapy (CKRT). We conducted a prospective observational study in two large teaching hospitals [Isala Hospital (IH) and Zwolle and Maasstad Hospital (MH)] to investigate target attainment and pharmacokinetics of cefotaxime in patients undergoing CKRT. Patients and methods: Patients aged ≥18 years admitted to the ICU treated with IV cefotaxime 1000 mg three times daily (IH) or 4 times daily (MH) were included. Fifteen patients were enrolled in total. Per patient eight cefotaxime plasma and eight ultrafiltrate samples were drawn in IH and four plasma samples in MH on Day 2 of treatment. In ICU patients the recommended antimicrobial target of cefotaxime is a plasma concentration 100% of the time above the MIC. Results: In IH 10/11 patients had higher plasma trough concentrations than the MIC breakpoint of Enterobacterales of 1 mg/L (clinical breakpoint for susceptible strains) and 9/11 patients had concentrations above 2 mg/L (clinical breakpoint for resistant strains). All patients (4/4) in MH had higher plasma trough concentrations than 2 mg/L. A sieving coefficient of 0.74 was identified, with a median amount of 40% of cefotaxime eliminated by CKRT. Conclusions: We conclude that cefotaxime 1000 mg 3–4 times daily gives adequate plasma concentrations in patients with anuria or oliguria undergoing CKRT. The 1000 mg four times daily dosage is recommended in patients undergoing CKRT with partially preserved renal function to achieve the target.

1 February 2024 in Current Drug Safety
Verified
Journal Article
Closed access
PDF file
AWAndré Wieringa
André Wieringa
HFHelle-Brit Fiebrich
Helle-Brit Fiebrich
FGFleur van Gelder
Fleur van Gelder
AVAbraham J. Valkenburg
Abraham J. Valkenburg
JMJan Gerard Maring
Jan Gerard Maring
ESElise J. Smolders
Elise J. Smolders
Background: Phenprocoumon is a vitamin K antagonist that is widely prescribed in Europe and Latin America for the prophylaxis and treatment of thromboembolic events. Case presentation: A 90-year-old female was admitted to our hospital with tonic-clonic seizures, possibly due to dementia syndrome. Discussion: Valproic acid (VPA) was prescribed for the treatment of seizures. VPA is an inhibitor of cytochrome P450 (CYP) 2C9 enzymes. A pharmacokinetic interaction with phenprocoumon occurred, which is a substrate for CYP2C9 enzymes. The interaction resulted in a strong INR increase and subsequent clinically relevant bleeding in our patient. Valproic acid is not specifically mentioned in the phenprocoumon drug label as a CYP2C9 inhibitor, and in the Dutch medication surveillance database, no medication alert is shown when prescribing this combination, and no interaction with phenprocoumon has been reported so far. Conclusion: When prescribing this combination, the prescriber should be warned and advised to intensify INR monitoring if the combination is to be continued.